Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314967 | 0.89 | AKR1C3 (0.45) | AVPR1AMAPTMEN1KMT2A | |
| SCHEMBL15451275 | 0.86 | TRPV1 (0.42) | AVPR1AKCNH2 | |
| SCHEMBL315881 | 0.86 | MEN1 (0.52) | MAPTNPSR1MEN1ALDH1A1KMT2A | |
| SCHEMBL10189997 | 0.86 | AVPR1A (0.47) | AVPR1AMAPTHSD11B1MEN1ALDH1A1 | |
| SCHEMBL314899 | 0.84 | AVPR1A (0.43) | AVPR1AKCNH2AVPR2ENPP2MAPT | |
| SCHEMBL316211 | 0.84 | AVPR1A (0.49) | AVPR1AHSD11B1ALDH1A1TP53 | |
| SCHEMBL314612 | 0.84 | MGLL (0.43) | AVPR1AHSD11B1 | |
| SCHEMBL15451324 | 0.83 | MEN1 (0.51) | AVPR1ASLC2A1MAPTMEN1ALDH1A1 | |
| SCHEMBL315732 | 0.83 | MGLL (0.52) | AVPR1AHSD11B1MEN1KMT2A | |
| SCHEMBL315469 | 0.82 | AKR1C3 (0.41) | AVPR1AMAPTHSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MAPK11 3006/4885MAPK14 3077/4885AVPR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.